Latest Data from SURPASS-3 Trial Gleans Insight Into the Association of Tirzepatide Treatment with Changes in Muscle Composition in Type 2 Diabetes

Contributed by: Business Wire

Logo

Business Wire logo

Images

A recent post-hoc analysis of Lilly’s SURPASS-3 trial unravels the impact of tirzepatide treatment on muscle volume and fat infiltration in individuals with Type 2 Diabetes
A recent post-hoc analysis of Lilly’s SURPASS-3 trial unravels the impact of tirzepatide treatment on muscle volume and fat infiltration in individuals with Type 2 Diabetes
Business Wire embedded0

Tags

Health
Diabetes
Clinical Trials
Research
Science
Pharmaceutical
Biotechnology
AMRA Medical

More Like This

AMRA Medical's Personalized Fat Z-scores (Photo: Business Wire)

AMRA Medical’s Innovative Fat Z-Score Biomarkers Show Tirzepatide Treatment is Associated with a Potential Targeted Effect on Visceral Fat and Liver Fat

Credit: Collaboration with Dr. Ian J Neeland, University Hospitals Cleveland. Data from NCT03038620 (ClinicalTrials.gov identifier) analysed with AMRA® Researcher

AMRA Medical’s Muscle Composition Analysis Used to Evaluate the Effect of Liraglutide Treatment in Obesity

MRI-based muscle assessment - Determining the relationship between drug-induced weight reduction and muscle health (Photo: Business Wire)

Adapting To Change: New Focused Review in Circulation Explores The Relationship Between Weight Reduction and Muscle Health

AMRA's muscle biomarkers - Research study explore changes in lean muscle volume (LMV), muscle fat fraction (MFF), and muscle fat infiltration (MFI)

Decoding Duchenne Muscular Dystrophy: MRI Study Explores the Relationship Between AMRA’s Muscle Biomarkers and Functional Changes in Individuals With DMD

A rapid, non-invasive, clinical surveillance for CachExia, sarcopenia, portal hypertension, and hepatocellular carcinoma in end-stage liver disease: the ACCESS-ESLD study protocol (Photo: Business Wire)

Baseline Enrollment Completed for AMRA Medical and Linköping University’s Landmark Liver Disease Study

Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation

In-depth analysis showing robust Diamyd® treatment effects across clinical trials to be shared at the 2024 IDS Diabetes Congress

GlobeNewswire associated0

Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study